Wells Fargo & Co. reissued their underperform rating on shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) in a research report report published on Tuesday morning. The brokerage currently has a $19.50 target price on the specialty pharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on VRX. JPMorgan Chase & Co. reiterated a hold rating and set a $35.00 price objective (down from $50.00) on shares of Valeant Pharmaceuticals International in a research report on Wednesday, June 22nd. Royal Bank Of Canada reissued a sector perform rating on shares of Valeant Pharmaceuticals International in a research report on Monday, June 27th. BMO Capital Markets assumed coverage on shares of Valeant Pharmaceuticals International in a research report on Tuesday, June 28th. They set a market perform rating and a $26.00 target price for the company. Stifel Nicolaus reissued a buy rating and set a $55.00 target price on shares of Valeant Pharmaceuticals International in a research report on Wednesday, July 6th. Finally, Rodman & Renshaw reaffirmed a buy rating and set a $90.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Wednesday, July 6th. Six equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $56.45.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded up 0.23% during mid-day trading on Tuesday, hitting $22.12. The company had a trading volume of 2,582,547 shares. Valeant Pharmaceuticals International has a 52-week low of $18.55 and a 52-week high of $162.90. The stock’s 50-day moving average is $26.21 and its 200-day moving average is $26.75. The stock’s market cap is $7.69 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.48 by $0.08. The company earned $2.42 billion during the quarter, compared to the consensus estimate of $2.47 billion. Valeant Pharmaceuticals International had a negative net margin of 9.29% and a positive return on equity of 46.59%. Valeant Pharmaceuticals International’s quarterly revenue was down 11.4% on a year-over-year basis. During the same period in the prior year, the company posted $2.14 EPS. Equities analysts forecast that Valeant Pharmaceuticals International will post $6.53 earnings per share for the current year.

In other Valeant Pharmaceuticals International news, Director Argeris N. Karabelas purchased 4,000 shares of the firm’s stock in a transaction on Thursday, August 11th. The shares were purchased at an average cost of $24.65 per share, with a total value of $98,600.00. Following the completion of the purchase, the director now owns 20,726 shares of the company’s stock, valued at approximately $510,895.90. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 16.37% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of VRX. Legal & General Group Plc boosted its position in shares of Valeant Pharmaceuticals International by 2.8% in the first quarter. Legal & General Group Plc now owns 1,209,137 shares of the specialty pharmaceutical company’s stock valued at $31,830,000 after buying an additional 33,247 shares in the last quarter. Okumus Fund Management Ltd. boosted its position in shares of Valeant Pharmaceuticals International by 98.5% in the first quarter. Okumus Fund Management Ltd. now owns 3,722,464 shares of the specialty pharmaceutical company’s stock valued at $97,901,000 after buying an additional 1,846,864 shares in the last quarter. LPL Financial LLC boosted its position in shares of Valeant Pharmaceuticals International by 65.5% in the first quarter. LPL Financial LLC now owns 91,050 shares of the specialty pharmaceutical company’s stock valued at $2,616,000 after buying an additional 36,046 shares in the last quarter. Seven Eight Capital LLC purchased a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $374,000. Finally, Riggs Asset Managment Co. Inc. boosted its position in shares of Valeant Pharmaceuticals International by 1.4% in the second quarter. Riggs Asset Managment Co. Inc. now owns 14,044 shares of the specialty pharmaceutical company’s stock valued at $283,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 63.67% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.